ZIVOZivo Bioscience Inc

Quick Summary

ZIVO Bioscience Inc is a biotech and agtech company specializing in the development, licensing, and sale of natural bioactive ingredients derived from proprietary algae cultures. The company’s offerings are primarily targeted towards manufacturers and companies in the animal health, human health, dietary supplement, and medical food sectors. ZIVO’s focus is on supplying specialized ingredients that offer unique nutritional and health benefits, with a strong emphasis on natural antioxidants and immune-enhancing compounds. Their innovations are intended for use in both animal feeds and human nutraceuticals, appealing to B2B customers that cater to consumer and commercial health markets. Main customers include large nutraceutical firms, animal health product manufacturers, and companion animal companies seeking novel, natural alternatives for improved health outcomes.

Key Risks

• ZIVO’s key risks include ongoing liquidity and funding challenges, which could threaten operations if not addressed through successful capital raising.
• The company’s dependence on a limited number of near-term partnership deals poses concentration risk; failure to close these deals could delay or derail growth plans.
• Competitive threats from better-funded peers or new technological entrants are significant.
• Regulatory or scientific setbacks, such as delays in approvals or negative study results, could harm market prospects.

What to Watch

Price Drivers

• The price of ZIVO Bioscience’s stock is primarily driven by advancements in commercial partnerships, technology validation, and regulatory progress in both human and animal health applications.
• Investor confidence is influenced by announcements of breakthrough study results, new licensing or commercialization agreements, and strategic investments by management.
• Macroeconomic events such as rising demand for natural, antibiotic-free animal products, global health trends, and regulatory changes in food and feed industries play a significant role.
• The company’s relatively low liquidity and small market capitalization also make its share price highly sensitive to volume and speculative investor activity.

Recent News

• The most recent news from September 2025 highlights significant technical achievements and new strategic directions at ZIVO Bioscience.
• The company saw independent confirmation that its algae provides outstanding antioxidant benefits and is now in advanced discussions with major global nutraceutical firms to commercialize its products.
• In the animal health market, ZIVO’s natural algae feed has been shown to reduce disease transmission and improve immunity in poultry, sparking global interest from animal health and pet food companies.
• The board and management’s personal investment underscores confidence despite continued liquidity issues, and capital raises are in planning.

Market Trends

• ZIVO operates in markets shaped by surging demand for natural, antibiotic-free food and feed ingredients, driven by growing consumer and regulatory focus on health, food safety, and transparency.
• The global trend away from antibiotics in livestock production, along with a preference for plant-based and minimally processed ingredients, creates a favorable backdrop for ZIVO’s algae-based innovations.
• There’s a strong push from food and health regulators to reduce antibiotic resistance, accelerating interest in immune-boosting natural alternatives.
• In parallel, the nutraceutical and functional foods sectors are experiencing rapid growth as consumers seek proactive, science-backed wellness solutions.